KeyBanc lowered the firm’s price target on Phreesia (PHR) to $12 from $15 and keeps an Overweight rating on the shares. Ahead of Q1 earnings, the firm believes the setup is largely positive, with beats likely across the group. That said, KeyBanc thinks most companies will reiterate their full-year guidance given the uncertain macro. Thematically, it believes healthcare systems are continuing to see good utilization, supporting capex/ software spend, and Pharma digital advertising environment remains choppy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHR:
- William Blair healthcare IT analysts hold analyst/industry conference call
- Phreesia price target lowered to $15 from $25 at Wells Fargo
- Buy Rating on Valuation and Earnings Power as Market Overreacts to Concentrated Slowdown Risks
- Phreesia Earnings Call: Profit Breakthrough, Growth Reset
- Integration Risks Cloud Phreesia’s AccessOne Deal, Threatening Synergies and Share Performance